New study checks if dupixent makes life better for severe asthma patients
NCT ID NCT06018441
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 112 adults with severe asthma who were starting treatment with dupilumab (Dupixent). Researchers measured changes in quality of life using a standard questionnaire at 12, 24, and 52 weeks. The goal was to see if the drug helps people feel better and breathe easier in everyday life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dupilumab (Dupixent)
- What this could lead to
- If successful, this could show that dupilumab improves daily life for people with severe asthma, supporting its use in routine care.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. It also only includes people already starting dupilumab, which may bias outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site
France, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a single injection tame severe asthma in fungal allergy?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?